IRIS Accounts Production v26.1.0.640 02462121 Board of Directors 1.9.24 31.8.25 31.8.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh024621212024-08-31024621212025-08-31024621212024-09-012025-08-31024621212023-08-31024621212023-09-012024-08-31024621212024-08-3102462121ns15:EnglandWales2024-09-012025-08-3102462121ns14:PoundSterling2024-09-012025-08-3102462121ns10:Director12024-09-012025-08-3102462121ns10:PrivateLimitedCompanyLtd2024-09-012025-08-3102462121ns10:SmallEntities2024-09-012025-08-3102462121ns10:AuditExempt-NoAccountantsReport2024-09-012025-08-3102462121ns10:SmallCompaniesRegimeForDirectorsReport2024-09-012025-08-3102462121ns10:SmallCompaniesRegimeForAccounts2024-09-012025-08-3102462121ns10:FullAccounts2024-09-012025-08-3102462121ns10:Director52024-09-012025-08-3102462121ns10:Director62024-09-012025-08-3102462121ns10:Director72024-09-012025-08-3102462121ns10:Director82024-09-012025-08-3102462121ns10:RegisteredOffice2024-09-012025-08-3102462121ns5:CurrentFinancialInstruments2025-08-3102462121ns5:CurrentFinancialInstruments2024-08-3102462121ns5:Non-currentFinancialInstruments2025-08-3102462121ns5:Non-currentFinancialInstruments2024-08-3102462121ns5:ShareCapital2025-08-3102462121ns5:ShareCapital2024-08-3102462121ns5:CapitalRedemptionReserve2025-08-3102462121ns5:CapitalRedemptionReserve2024-08-3102462121ns5:FurtherSpecificReserve1ComponentTotalEquity2025-08-3102462121ns5:FurtherSpecificReserve1ComponentTotalEquity2024-08-3102462121ns5:RetainedEarningsAccumulatedLosses2025-08-3102462121ns5:RetainedEarningsAccumulatedLosses2024-08-3102462121ns5:PlantMachinery2024-09-012025-08-3102462121ns5:PlantMachinery2024-08-3102462121ns5:PlantMachinery2025-08-3102462121ns5:PlantMachinery2024-08-3102462121ns5:WithinOneYearns5:CurrentFinancialInstruments2025-08-3102462121ns5:WithinOneYearns5:CurrentFinancialInstruments2024-08-31
REGISTERED NUMBER: 02462121 (England and Wales)















RED Scientific Reply Limited

Financial Statements for the Year Ended 31st August 2025






RED Scientific Reply Limited (Registered number: 02462121)

Contents of the Financial Statements
for the Year Ended 31st August 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


RED Scientific Reply Limited

Company Information
for the Year Ended 31st August 2025







DIRECTORS: Mrs Y J Whiteley
M D Brule-Walker
J S Hill
M Cusinato
F Rizzante





REGISTERED OFFICE: 38 Grosvenor Gardens
London
SW1W 0EB





BUSINESS ADDRESS: 1 Oriel Court
Omega Park
Alton
Hampshire
GU34 2YT





REGISTERED NUMBER: 02462121 (England and Wales)





ACCOUNTANTS: Sheen Stickland
Chartered Accountants
The Engine House
77 Station Road
Petersfield
Hampshire
GU32 3FQ

RED Scientific Reply Limited (Registered number: 02462121)

Balance Sheet
31st August 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 36,211 34,635

CURRENT ASSETS
Debtors 5 1,173,627 1,125,247
Cash at bank and in hand 448,269 754,609
1,621,896 1,879,856
CREDITORS
Amounts falling due within one year 6 740,347 643,003
NET CURRENT ASSETS 881,549 1,236,853
TOTAL ASSETS LESS CURRENT
LIABILITIES

917,760

1,271,488

CREDITORS
Amounts falling due after more than
one year

7

(41,667

)

(91,667

)

PROVISIONS FOR LIABILITIES (6,593 ) (6,042 )
NET ASSETS 869,500 1,173,779

RED Scientific Reply Limited (Registered number: 02462121)

Balance Sheet - continued
31st August 2025

2025 2024
Notes £    £    £    £   
CAPITAL AND RESERVES
Called up share capital 38,720 32,920
Capital redemption reserve 47,600 47,600
Share-based payment reserve - 9,503
Retained earnings 783,180 1,083,756
SHAREHOLDERS' FUNDS 869,500 1,173,779

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 11th May 2026 and were signed on its behalf by:





Mrs Y J Whiteley - Director


RED Scientific Reply Limited (Registered number: 02462121)

Notes to the Financial Statements
for the Year Ended 31st August 2025


1. STATUTORY INFORMATION

RED Scientific Reply Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents invoiced services, net of value added tax, together with the percentage of associated revenue on work not invoiced but in progress at the year end.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost and 15% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

RED Scientific Reply Limited (Registered number: 02462121)

Notes to the Financial Statements - continued
for the Year Ended 31st August 2025


2. ACCOUNTING POLICIES - continued

Research and development
Expenditure on research and development is written off in the year in which it is incurred.

Research and development tax credits are recognised in the year that they accrue. Deferred tax credits are recognised only to the extent that it is probable that they will be recovered against future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Share-based payments for employee share schemes
The company had previously granted share options to certain directors and employees, all of whom were based in the UK. The fair value was charged as an expense in the profit and loss account over the vesting period with a credit entry contained within a separate reserve called the Share-Based Payment Reserve.

All options had been exercised by 31st August 2025.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 39 (2024 - 37 ) .

RED Scientific Reply Limited (Registered number: 02462121)

Notes to the Financial Statements - continued
for the Year Ended 31st August 2025


4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1st September 2024 78,947
Additions 17,847
At 31st August 2025 96,794
DEPRECIATION
At 1st September 2024 44,312
Charge for year 16,271
At 31st August 2025 60,583
NET BOOK VALUE
At 31st August 2025 36,211
At 31st August 2024 34,635

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 427,812 387,943
Other debtors 745,815 737,304
1,173,627 1,125,247

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Bank loans and overdrafts 50,000 50,000
Trade creditors 172,577 222,081
Taxation and social security 134,487 146,182
Other creditors 383,283 224,740
740,347 643,003

RED Scientific Reply Limited (Registered number: 02462121)

Notes to the Financial Statements - continued
for the Year Ended 31st August 2025


7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2025 2024
£    £   
Bank loans 41,667 91,667

8. SECURED DEBTS

The following secured debts are included within creditors:

2025 2024
£    £   
Bank loans 18,333 28,333

The company is repaying a loan granted under the Coronavirus Business Interruption Loan Scheme. In the event of default by the company, repayment of the loan and interest is backed by an 80% UK government guarantee.

9. SHARE-BASED PAYMENT TRANSACTIONS

During the year the remaining granted share options were exercised. There are no options outstanding on 31st August 2025.

The involvement of the employees in the share scheme arrangements is as follows:

20252024
£ £
Charge to profit and loss during the period(9,503)-
Balance arising from share-based payments at end of the period-9,503